218th ENMC International Workshop: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19–21 February 2016

@article{Finkel2017218thEI,
  title={218th ENMC International Workshop: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19–21 February 2016},
  author={Richard S. Finkel and Thomas Sejersen and Eugenio Mercuri and Enrico Bertini and K. Chen and T. O. Crawford and Victor Dubowitz and Menc{\'i}a de Lemus and R. Graham and R. Davis and Salvatore Iannaccone and Jana Kirschner and Marion Main and O. Mayer and Elena Stacy Mazzone and J. Montes and Francesco Muntoni and Alexander Peter Murphy and S. Quijano-roy and Agata Robertson and Mary Schroth and Ak Simonds and Brian Snyder and Maria Ama{\`i}lia Faller Vitale and Andreas Wittchen and Sara Woods and Ying Qian and B. Wirth},
  journal={Neuromuscular Disorders},
  year={2017},
  volume={27},
  pages={596-605}
}
218th ENMC International Workshop: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19–21 February 2016 Richard S. Finkel , Thomas Sejersen , Eugenio Mercuri * on behalf of the ENMC SMA Workshop Study Group 1 a Pediatric Neurology, Nemours Children’s Hospital, Orlando, FL, USA b Pediatric Neurology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden c Pediatric Neurology, Policlinico Gemelli, Catholic University and Centro Nemo, Rome, Italy 
Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care
TLDR
The results indicate that the pathway of care described outweighs the burden due to the repeated intrathecal injections and the treatment is feasible, accessible, and replicable provided that there is a multidisciplinary team having experience and training in SMA. Expand
Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
TLDR
The methods used to achieve these recommendations are presented, and an update on diagnosis, rehabilitation, orthopedic and spinal management; and nutritional, swallowing and gastrointestinal management are presented. Expand
[Spinal muscular atrophy in samara region. Epidemiology, classification, prospects for health care].
TLDR
The authors discuss the classification and etiopathogenesis of spinal muscular atrophy, prospects for its pathogenetic therapy and prevention in Russia, in particular in Samara region. Expand
Spinal muscular atrophy: A changing phenotype beyond the clinical trials
TLDR
A perspective review discusses potential new trajectories in the phenotype of SMA and the need for multidisciplinary teams to prepare for this changing landscape. Expand
Direct Medical Costs of Spinal Muscular Atrophy in the Catalonia Region: A Population-Based Analysis
  • J. Darbà
  • Medicine
  • Clinical Drug Investigation
  • 2020
TLDR
Inpatient extended care and the increased presence of multimorbid chronic conditions in patients with SMA must be taken into account in order to develop multidisciplinary treatment protocols that reflect the complexity of SMA. Expand
Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
TLDR
This part includes updated recommendations on pulmonary management and acute care issues, and topics that have emerged in the last few years such as other organ involvement in the severe forms of spinal muscular atrophy and the role of medications. Expand
Multidisciplinary approach and psychosocial management of spinal muscular atrophy (SMA).
TLDR
This part focuses on multidisciplinary management of SMA, pluridisciplinary consultations, emergency management, psychosocial care and transitions to adulthood. Expand
Transition to adult care in young people with neuromuscular disease on non-invasive ventilation
TLDR
Patients with NMDs on NIV in age to Transition to adult require complex multidisciplinary management: significant efforts are needed to achieve the proper transition to adult care. Expand
Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases
TLDR
A database of 3459 patients is assembled to delineate more universal prognostic rules regarding the influence of SMN2 copy number on SMA phenotype and to establish careful genotype-phenotype correlations, predict disease evolution, and to stratify patients for clinical trials. Expand
An overview of the Cure SMA membership database: Highlights of key demographic and clinical characteristics of SMA members
TLDR
The Cure SMA database is a unique and robust source of patient reported data that informs on the burden of illness and supports the development of new therapeutic modalities. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 49 REFERENCES
209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7–9 November 2014, Heemskerk, The Netherlands
209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7–9 November 2014, Heemskerk, The Netherlands Richard Finkel *, Enrico Bertini , FrancescoExpand
Long-Term Survival in Werdnig–Hoffmann Disease
TLDR
NIV and tracheostomy can both prolong survival for SMA 1 patients, but the latter results in continuous ventilator dependence and speech does not develop. Expand
Spinal Muscular Atrophy Type I
TLDR
How autonomy, beneficence/non-maleficence, noncoercion, social benefit, and equipoise can be maintained when a predefined level of supportive care is proposed, for participation in a clinical trial is discussed. Expand
Genotype–phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling
TLDR
The observed clinical variability, especially in the group with two SMN2 copies, might be important for clinical trials in SMA I where a possible control group could be defined as follows: age at onset within 4–5 months, age at genetic diagnosis <6 months, two SMn2 copies present, head control in less than 10%, no respiratory distress from birth, disease endpoint either age at death or age at permanent ventilation. Expand
Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications.
TLDR
The definition of long-term characteristics of SMA is helpful in providing medical care to families with members who have SMA and also in providing important information for future genotype-phenotype studies and therapeutic trials of patients with SMA. Expand
Observational study of spinal muscular atrophy type I and implications for clinical trials
TLDR
Infants with SMA-I can be effectively enrolled and retained in a 12-month natural history study until a majority reach the combined endpoint of death, and these outcome data can be used for clinical trial design. Expand
A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients
TLDR
Clinical data provide a reliable basis of the natural history of proximal SMA and support a classification system that is based primarily on age at onset and the achievement of motor milestones. Expand
Survival in SMA type I: A prospective analysis of 34 consecutive cases
TLDR
All deceased children died of respiratory insufficiency and/or an intercurrent lung infection, indicating that the susceptibility of the child with SMA type I to respiratory infections plays an important role in determining the survival. Expand
Spinal muscular atrophy–type I
The challenge of defining a child’s best interests Spinal muscular atrophy–type I or Werdnig-Hoffman disease is an autosomal recessive disorder of childhood that causes profound weakness and deathExpand
Acute Werdnig-Hoffmann disease
TLDR
76 cases of acute Werdnig-Hoffmann disease (acute infantile spinal muscular atrophy) have been reviewed and Cumulative frequency curves for age at onset and age at death figures are presented for use both as prognostic guidelines and in the management of sibs of index cases. Expand
...
1
2
3
4
5
...